Silver(I) Complexes Based on Oxadiazole-Functionalized a-Aminophosphonate: Synthesis, Structural Study, and Biological Activities
| dc.authorid | 0000-0003-1498-4170 | tr |
| dc.contributor.author | Hkiri, Shaima | |
| dc.contributor.author | Açıkalın Coşkun, Kübra | |
| dc.contributor.author | Üstün, Elvan | |
| dc.contributor.author | Samarat, Ali | |
| dc.contributor.author | Tutar, Yusuf | |
| dc.contributor.author | Şahin, Neslihan | |
| dc.contributor.author | Sémeril, David | |
| dc.date.accessioned | 2023-04-03T05:53:41Z | |
| dc.date.available | 2023-04-03T05:53:41Z | |
| dc.date.issued | 2022 | tr |
| dc.department | Eğitim Fakültesi | tr |
| dc.description.abstract | Two silver(I) complexes, bis{diethyl[(5-phenyl-1,3,4-oxadiazol-2-yl- N3: N4-amino) (4- trifluoromethylphenyl)methyl]phosphonate-(tetrafluoroborato- F)}-di-silver(I) and tetrakis-{diethyl [(5-phenyl-1,3,4-oxadiazol-2-yl- N3-amino)(4-trifluoromethylphenyl)methyl]phosphonate} silver(I) tetrafluoroborate, were prepared starting from the diethyl[(5-phenyl-1,3,4-oxadiazol-2-yl-amino)(4- trifluoromethylphenyl)methyl]phosphonate (1) ligand and AgBF4 salt in Ag/ligand ratios of 1/1 and 1/4, respectively. The structure, stoichiometry, and geometry of the silver complexes were fully characterized by elemental analyses, infrared, single-crystal X-ray diffraction studies, multinuclear NMR, and mass spectroscopies. The binuclear complex ([Ag2(1)2(BF4)2]; 2) crystallizes in the monoclinic asymmetric space group P21/c and contains two silver atoms adopting a {AgN2F} planar trigonal geometry, which are simultaneously bridged by two oxadiazole rings of two ligands, while the mononuclear complex ([Ag(1)4]BF4; 3) crystallizes in the non-usual cubic space group Fd-3c in which the silver atom binds to four distinct electronically enriched nitrogen atoms of the oxadiazole ring, in a slightly distorted {AgN4} tetrahedral geometry. The a-aminophosphonate and the monomeric silver complex were evaluated in vitro against MCF-7 and PANC-1 cell lines. The silver complex is promising as a drug candidate for breast cancer and the pancreatic duct with half-maximal inhibitory concentration (IC50) values of 8.3 1.0 and 14.4 0.6 M, respectively. Additionally, the interactions of the ligand and the mononuclear complex with Vascular Endothelial Growth Factor Receptor-2 and DNA were evaluated by molecular docking methods. | tr |
| dc.identifier.uri | https://hdl.handle.net/20.500.12418/13254 | |
| dc.language.iso | en | en_US |
| dc.relation.publicationcategory | Rapor | tr |
| dc.rights | info:eu-repo/semantics/closedAccess | tr |
| dc.title | Silver(I) Complexes Based on Oxadiazole-Functionalized a-Aminophosphonate: Synthesis, Structural Study, and Biological Activities | en_US |
| dc.type | Article | en_US |
